Indivior PLCNASDAQ:INDV
- LAST PRICE9.8600
- TODAY'S CHANGE (%)0.0400 (0.4073%)
- Bid / Lots9.8500/ 6
- Ask / Lots9.8700/ 6
- Open / Previous Close9.7700 / 9.8200
- Day Range
- 52 Week Range
- Volume402,272
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INDV |
|---|---|---|
| 09:32 ET | 7725 | 9.75 |
| 09:37 ET | 200 | 9.77 |
| 09:42 ET | 200 | 9.75 |
| 09:44 ET | 5484 | 9.75 |
| 09:46 ET | 23989 | 9.68 |
| 09:48 ET | 600 | 9.65 |
| 09:50 ET | 912 | 9.65 |
| 09:53 ET | 4160 | 9.645 |
| 09:55 ET | 100 | 9.64 |
| 09:57 ET | 200 | 9.64 |
| 10:00 ET | 3229 | 9.63 |
| 10:02 ET | 3247 | 9.63 |
| 10:04 ET | 7391 | 9.68 |
| 10:06 ET | 7556 | 9.68 |
| 10:08 ET | 4497 | 9.67 |
| 10:09 ET | 2321 | 9.66 |
| 10:11 ET | 3394 | 9.655 |
| 10:13 ET | 2100 | 9.645 |
| 10:15 ET | 3326 | 9.63 |
| 10:20 ET | 2646 | 9.645 |
| 10:22 ET | 900 | 9.645 |
| 10:24 ET | 500 | 9.65 |
| 10:26 ET | 13737 | 9.62 |
| 10:29 ET | 3300 | 9.645 |
| 10:31 ET | 6682 | 9.68 |
| 10:33 ET | 4020 | 9.69 |
| 10:38 ET | 9570 | 9.72 |
| 10:40 ET | 3207 | 9.72 |
| 10:42 ET | 3302 | 9.71 |
| 10:44 ET | 1800 | 9.705 |
| 10:45 ET | 14826 | 9.71 |
| 10:47 ET | 5150 | 9.71 |
| 10:49 ET | 400 | 9.71 |
| 10:51 ET | 2825 | 9.715 |
| 10:54 ET | 2425 | 9.73 |
| 10:56 ET | 500 | 9.73 |
| 10:58 ET | 11400 | 9.7601 |
| 11:00 ET | 22383 | 9.735 |
| 11:02 ET | 200 | 9.74 |
| 11:03 ET | 7217 | 9.77 |
| 11:05 ET | 992 | 9.775 |
| 11:07 ET | 1200 | 9.785 |
| 11:09 ET | 695 | 9.77 |
| 11:12 ET | 100 | 9.775 |
| 11:14 ET | 200 | 9.77 |
| 11:16 ET | 100 | 9.765 |
| 11:18 ET | 4444 | 9.73 |
| 11:20 ET | 19009 | 9.71 |
| 11:21 ET | 2629 | 9.715 |
| 11:23 ET | 811 | 9.715 |
| 11:25 ET | 1900 | 9.72 |
| 11:27 ET | 16821 | 9.75 |
| 11:30 ET | 2100 | 9.75 |
| 11:32 ET | 700 | 9.77 |
| 11:34 ET | 10449 | 9.775 |
| 11:36 ET | 10510 | 9.78 |
| 11:38 ET | 400 | 9.78 |
| 11:39 ET | 3669 | 9.8 |
| 11:41 ET | 631 | 9.8 |
| 11:43 ET | 500 | 9.795 |
| 11:45 ET | 10484 | 9.825 |
| 11:48 ET | 4554 | 9.84 |
| 11:50 ET | 7600 | 9.86 |
| 11:52 ET | 16174 | 9.87 |
| 11:56 ET | 1192 | 9.84 |
| 11:57 ET | 500 | 9.85 |
| 11:59 ET | 1000 | 9.84 |
| 12:01 ET | 900 | 9.84 |
| 12:03 ET | 2510 | 9.85 |
| 12:06 ET | 1241 | 9.86 |
Nov 7, 2024
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior, from 2:24PM ET on Thursday Nov 07, 2024 by Dow Jones
2:24PM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 30, 2024
Indivior Highlights Growing Body of Data on SUBLOCADE(R) (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month, from 12:30PM ET on Wednesday Oct 30, 2024 by Dow Jones
12:30PM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 25, 2024
DJ Indivior Price Target Raised to $16.00/Share From $15.00 by Piper Sandler, from 11:00AM ET on Friday Oct 25, 2024 by Dow Jones
11:00AM ET on Friday Oct 25, 2024 by Dow Jones
Oct 24, 2024
Indivior Announces Q3 2024 Financial Results, from 2:00AM ET on Thursday Oct 24, 2024 by Dow Jones
2:00AM ET on Thursday Oct 24, 2024 by Dow JonesPress Release: Indivior Announces Q3 2024 Financial Results, from 2:00AM ET on Thursday Oct 24, 2024 by Dow Jones
2:00AM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Indivior PLC | 986.8M | 0.0x | --- |
Company Information
Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
Contact Information
- Headquarters
- 10710 Midlothian Turnpike Suite 125, North ChesterfieldCHESTERFIELD, VA, United States 23235
- Phone
- 804-379-1090
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $986.8M |
|---|---|
Revenue (TTM) | $909.1M |
Shares Outstanding | 126.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.13 |
EPS | $-0.86 |
Book Value | $0.00 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
